Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12821486 | 0.99 | SYK (0.57) | SYKSCN9AEGFRSCN5AKCNH2 | |
| Hydrochloric Acid SCHEMBL12821490 | 0.87 | SYK (0.57) | SYKSCN9AEGFRSCN5AKCNH2 | |
| SCHEMBL31156708 | 0.80 | SYK (0.63) | SYKEGFRBTK | |
| SCHEMBL2744987 | 0.79 | CDC7 (0.59) | SYKSCN9AEGFR | |
| SCHEMBL29430407 | 0.79 | CDC7 (0.59) | SYKSCN9AEGFR | |
| SCHEMBL22803906 | 0.79 | SYK (0.63) | SYKEGFRBTK | |
| SCHEMBL12968742 | 0.77 | MAPKAPK2 (0.58) | SYKEGFR | |
| SCHEMBL29430445 | 0.77 | SYK (0.74) | SYKEGFR | |
| SCHEMBL2745468 | 0.77 | SYK (0.74) | SYKEGFR | |
| Hydrochloric Acid SCHEMBL12821383 | 0.76 | MAPKAPK2 (0.56) | SYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-8178671-B2 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | SYK 2275/4885SCN9A 4198/4885EGFR 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.